Evidence map›Paper›PMID 41850239›Full record

ArticleCell reports. Medicine2026

TET CpG sequence-context-specific DNA demethylation shapes progression of IDH-mutant gliomas.

Youri Hoogstrate, Santoesha A Ghisai, Levi van Hijfte, Rania Head, Iris de Heer, Marta Padovan, Maurice de Wit, Wies R Vallentgoed, Angelo Dipasquale, Maarten M J Wijnenga and 24 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors.

Youri HoogstrateDepartment of Neurology, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, the Netherlands. Electronic address: y.hoogstrate@erasmusmc.nl.
Santoesha A GhisaiDepartment of Neurology, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, the Netherlands.
Levi van HijfteDepartment of Neurosurgery, University Clinic Erlangen, Erlangen, Germany.
Rania HeadDepartment of Neurology, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, the Netherlands.
Iris de HeerDepartment of Neurology, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, the Netherlands.
Marta PadovanDepartment of Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy.
Maurice de WitDepartment of Neurology, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, the Netherlands.
Wies R VallentgoedDepartment of Neurology, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, the Netherlands.
Angelo DipasqualeRCCS Humanitas Research Hospital, Via Alessandro Manzoni 56, Rozzano, Milan, Italy.
Maarten M J WijnengaDepartment of Neurology, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, the Netherlands.
Bas WeeninkDepartment of Neurology, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, the Netherlands.
Rosa LuningDepartment of Neurology, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, the Netherlands.
Sybren L N MaasDepartment of Pathology, Erasmus MC Cancer Institute Erasmus MC, Rotterdam, the Netherlands; Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands.
Adela BrzobohataDepartment of Neurology, Clinical Neuroscience Center, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Michael WellerDepartment of Neurology, Clinical Neuroscience Center, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Tobias WeissDepartment of Neurology, Clinical Neuroscience Center, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Maximilian J MairDivision of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Anna S BerghoffDivision of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Adelheid WöhrerDepartment of Pathology, Neuropathology and Molecular Pathology, Medical University of Innsbruck, Innsbruck, Tyrol, Austria; Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Vienna, Austria.
Albert JeltschInstitute of Biochemistry and Technical Biochemistry, Department of Biochemistry, University of Stuttgart, Stuttgart, Germany.
Johan A F KoekkoekDepartment of Neurology, Leiden University Medical Center, Leiden, the Netherlands.
Hans M HazelbagDepartment of Pathology, Haaglanden MC, The Hague, the Netherlands.
Mathilde C M KouwenhovenDepartment of Neurology, Amsterdam UMC, Amsterdam, the Netherlands.
Yongsoo KimDepartment of Pathology, Amsterdam UMC, Cancer Center Amsterdam, Amsterdam, the Netherlands.
Bart A WestermanDepartment of Human Genetics, Amsterdam UMC, Amsterdam, the Netherlands.
Bauke YlstraDepartment of Pathology, Amsterdam UMC, Cancer Center Amsterdam, Amsterdam, the Netherlands.
Anneke M NiersDepartment of Neurology, Amsterdam UMC, Amsterdam, the Netherlands.
Kevin C JohnsonDepartment of Neurosurgery, Yale University, New Haven, CT, USA.
Frederick S VarnThe Jackson Laboratory for Genomic Medicine, Farmington, CT, USA; Department of Genetics and Genome Sciences, University of Connecticut Health Center, Farmington, CT, USA; Institute for Systems Genomics, University of Connecticut, Storrs, CT, USA.
Roel G W VerhaakDepartment of Neurosurgery, Yale University, New Haven, CT, USA.
Mustafa KhasrawDepartment of Neurosurgery, Duke University, Durham, NC, USA.
Martin J van den BentDepartment of Neurology, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, the Netherlands.
Pieter WesselingDepartment of Pathology, Amsterdam UMC, Cancer Center Amsterdam, Amsterdam, the Netherlands; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Pim J FrenchDepartment of Neurology, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Treatment decisions in IDH-mutant oligodendrogliomas are shaped by tumor aggressiveness, underscoring the need for objective grading of these malignant brain tumors. We collect 302 primary and recurrent resections from oligodendrogliomas and perform Ki-67 staining, proteomics, and DNA methylation profiling. During tumor progression, DNA methylation of oligodendrogliomas changes along a continuum. This continuum is linked to increased epigenetic aging, methylation of transcription factors and Ki-67+ cell density, and large-scale DNA demethylation. Demethylation correlates with CpG flanking sequences preferred by TET enzymes. We confirm these findings in previously profiled astrocytomas, indicating IDH-mutant gliomas progress along a shared epigenetic axis. We develop an objective DNA methylation-based prognostic continuous grading coefficient (CGC

Indexed as

Brain NeoplasmsCpG IslandsDNA DemethylationDNA MethylationGliomaIsocitrate DehydrogenaseMutationOligodendrogliomaDisease ProgressionEpigenesis, GeneticFemaleHumansIDH1 protein, humanIsocitrate Dehydrogenasecontinuous grading coefficientDNA-methylationIDH-mutant gliomaoligodendrogliomasequence contextTETtumor evolution

Identifiers

PMID41850239
PMCPMC13006442

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.